The firm and the company seem to have an amicable and constructive relationship, but there are still opportunities for value ...

Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...

Cameco looks like a solid option for investors to buy at current levels. I think the stock should be a long-term winner, although there could still be some near-term bumps. However, it's best to look ...

Find investment ideas for your portfolio with the latest stock picks from Barron’s below. These picks are the product of the Barron’s newsroom and are our best ideas based on original ...